CTTN Antibody

What is cortactin and why is it an important research target?

Cortactin (CTTN) is a cytoskeletal protein that plays a crucial role in regulating actin polymerization and cytoskeletal rearrangements. It is heavily involved in cell motility, invasion, and adhesion processes. The significance of cortactin in research stems from its phosphorylation at tyrosine residues 421, 466, and 482, which regulates multiple cellular functions including cell motility, Rac1-mediated actin dynamics, cadherin-dependent adhesion, and chemokine trafficking and chemokine-dependent chemotaxis . Dysregulation of CTTN has been linked to cancer progression and metastasis, making it a valuable target for oncology research . Understanding cortactin's function and expression patterns is essential for developing strategies to target cancer cells that rely on CTTN-mediated processes, particularly in breast carcinoma and other invasive cancers where cortactin overexpression has been documented .

Species reactivity is a critical consideration when selecting a CTTN antibody. Based on the available data, CTTN antibodies demonstrate the following cross-reactivity patterns:

When working with non-human samples, it's essential to select an antibody that has been specifically validated for your species of interest. Some antibodies may show cross-reactivity due to conserved epitopes, but this should be experimentally confirmed rather than assumed . For evolutionary studies or when working with less common model organisms, preliminary testing for cross-reactivity is strongly recommended, as the antibodies may recognize conserved epitopes in the CTTN protein across related species.

How do I differentiate between phosphorylated and non-phosphorylated cortactin in my experiments?

Differentiating between phosphorylated and non-phosphorylated forms of cortactin requires specific methodological approaches. Phosphorylation at tyrosine residues 421, 466, and 482 regulates cortactin's role in cell motility and actin dynamics . To effectively distinguish these forms:

• Use phospho-specific antibodies: Some antibodies, like the Anti-Cortactin (Y460) from Boster Bio, are specifically designed to recognize phosphorylated cortactin at defined residues (e.g., Y460) . These antibodies will only detect cortactin when phosphorylated at that specific site.

• Employ phosphatase treatment controls: Split your samples and treat one set with a phosphatase before immunoblotting. The phosphatase-treated sample should show reduced or absent signal with phospho-specific antibodies but maintained signal with total cortactin antibodies, confirming phospho-specificity.

• Two-dimensional gel electrophoresis: This technique separates proteins based on both isoelectric point and molecular weight, allowing visualization of phosphorylated forms as distinct spots from non-phosphorylated forms.

• Phos-tag™ SDS-PAGE: This modified gel system specifically retards the migration of phosphorylated proteins, creating a visible mobility shift between phosphorylated and non-phosphorylated forms of the same protein.

When analyzing cell migration or invasion experiments, correlating the levels of phosphorylated cortactin with phenotypic outcomes can provide insights into the functional significance of cortactin phosphorylation under different experimental conditions .

How can I investigate the interaction between cortactin and the actin cytoskeleton?

Investigating cortactin-actin interactions requires specialized techniques that preserve and detect these dynamic associations:

• Co-immunoprecipitation (Co-IP): Using CTTN antibodies validated for immunoprecipitation (such as H222 at 1:50 dilution), you can pull down cortactin along with its binding partners . Subsequent western blotting for actin can confirm their association. Crosslinking prior to lysis may help preserve transient interactions.

• Proximity Ligation Assay (PLA): This technique allows visualization of protein-protein interactions in situ. Use primary antibodies against cortactin and actin from different species, followed by species-specific secondary antibodies linked to complementary DNA strands. When proteins are in close proximity (<40 nm), the DNA strands can hybridize and be amplified, creating a detectable fluorescent signal.

• Immunofluorescence co-localization: Using antibodies validated for immunofluorescence (IF) applications like H222 (1:200) or A01253Y460 (1:50-1:100), perform dual-labeling experiments with cortactin and actin markers (phalloidin or actin antibodies) . Analyze co-localization using confocal microscopy and quantitative co-localization analysis software.

• FRET (Förster Resonance Energy Transfer): For live-cell imaging of cortactin-actin dynamics, express fluorescently tagged cortactin and actin, then use FRET microscopy to detect their direct interaction with nanometer resolution.

When analyzing results, consider that cortactin specifically associates with the Arp2/3 complex at sites of active actin polymerization, particularly in lamellipodia and invadopodia of migrating cells . Different experimental conditions (growth factors, inhibitors) can modulate these interactions, providing insights into regulatory mechanisms.

What strategies can address potential cross-reactivity issues when using CTTN antibodies in tumor samples?

When using CTTN antibodies in complex tumor samples, addressing cross-reactivity requires several strategic approaches:

• Comprehensive validation panel: Use multiple positive and negative control tissues/cell lines. Positive controls should include samples with known cortactin expression, while negative controls might include knockout/knockdown samples or tissues known not to express cortactin .

• Peptide competition assays: Pre-incubate your antibody with the immunizing peptide before applying to your sample. This should abolish specific staining while non-specific binding will persist, helping identify false positive signals.

• Multiple antibody validation: Compare results using different CTTN antibodies targeting distinct epitopes. Consistent staining patterns across different antibodies increase confidence in specificity .

• Orthogonal technology verification: Confirm protein expression using independent methods such as mass spectrometry or mRNA expression analysis (RT-PCR, RNA-seq).

• Careful antibody selection: Choose antibodies with minimal cross-reactivity profiles. For example, the CAB15054 antibody is specifically noted to have "No cross reactivity with other proteins" .

For tumor samples specifically, consider using antibody diluents with protein blockers to reduce non-specific binding to the abundant proteins present in tumor microenvironments. Additionally, optimize antigen retrieval methods for FFPE samples, as this can significantly impact staining specificity and intensity in immunohistochemistry applications .

What are the optimal storage conditions for maintaining CTTN antibody activity over time?

Proper storage is critical for maintaining antibody performance and extending shelf life. Based on manufacturer recommendations, the following storage practices should be followed:

• Long-term storage: Store CTTN antibodies at -20°C for maximum stability. The Boster Bio Anti-Cortactin antibody specifically recommends storage at -20°C for up to one year .

• Working stock storage: For frequent use over short periods (up to one month), store aliquots at 4°C to minimize freeze-thaw cycles .

• Aliquoting: Upon receipt, divide the antibody into small, single-use aliquots before freezing to avoid repeated freeze-thaw cycles, which can denature antibodies and reduce activity.

• Storage buffer considerations: Many CTTN antibodies are supplied in buffers containing glycerol (50%) and sodium azide (0.02%) as preservatives . Do not remove these components as they help maintain antibody stability.

• Temperature transitions: Allow frozen antibodies to thaw completely at room temperature or 4°C before opening to prevent condensation, which can introduce contaminants and accelerate degradation.

• Monitoring stability: If you observe decreased performance over time, it may indicate antibody degradation. Consider implementing a quality control system where you test each batch against a reference positive control to monitor performance consistency .

Following these guidelines will help ensure consistent experimental results and maximize the usable lifespan of your CTTN antibodies, ultimately improving research reproducibility and reducing costs associated with premature antibody replacement.

What sample preparation protocols optimize CTTN detection in different applications?

Optimal sample preparation varies significantly across applications to maximize CTTN detection. Here are application-specific recommendations:

For Western Blotting (WB):

• Lysis buffer: Use RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors (especially when studying phosphorylated forms).

• Sample handling: Maintain samples at 4°C during preparation to prevent protein degradation.

• Protein denaturation: Heat samples at 95°C for 5 minutes in Laemmli sample buffer (containing SDS and DTT) to ensure complete denaturation.

• Gel selection: Use 8-10% polyacrylamide gels to optimally resolve the 80-85 kDa cortactin protein .

• Transfer conditions: Transfer to PVDF membranes at constant voltage (25V) overnight at 4°C for large proteins like cortactin.

For Immunoprecipitation (IP):

• Gentle lysis: Use non-denaturing lysis buffers (e.g., NP-40 or Triton X-100 based) to preserve protein-protein interactions.

• Pre-clearing: Pre-clear lysates with protein A/G beads to reduce non-specific binding.

• Antibody ratio: Use CTTN antibody at 1:50 dilution for optimal immunoprecipitation efficiency .

• Incubation conditions: Perform antibody-lysate incubation overnight at 4°C with gentle rotation.

For Immunofluorescence (IF):

• Fixation: Use 4% paraformaldehyde for 15 minutes at room temperature to preserve cytoskeletal structures.

• Permeabilization: 0.1% Triton X-100 for 5 minutes is sufficient to allow antibody access without disrupting cytoskeletal architecture.

• Blocking: Block with 5% normal serum (from the same species as the secondary antibody) for at least 1 hour.

• Antibody dilution: Use recommended dilutions (1:50-1:200) in antibody diluent containing 1% BSA .

• Counterstaining: Consider co-staining with phalloidin to visualize F-actin, which often colocalizes with cortactin.

For Immunohistochemistry (IHC-P):

• Tissue fixation: 10% neutral buffered formalin for 24-48 hours is standard.

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is typically effective for CTTN antibodies.

• Blocking: Block endogenous peroxidase activity with 3% hydrogen peroxide followed by protein blocking.

• Antibody incubation: Use recommended dilutions (1:50-1:100) and incubate overnight at 4°C .

• Detection: DAB (3,3'-diaminobenzidine) substrate provides good contrast for visualization.

These protocols should be optimized for each specific antibody and sample type, as variations in fixation time, antibody concentration, and incubation conditions can significantly impact detection sensitivity and specificity .

How should I quantify and normalize CTTN expression data in comparative studies?

Accurate quantification and normalization of CTTN expression data is critical for meaningful comparative studies. Follow these evidence-based approaches for different experimental techniques:

For Western Blot Analysis:

• Loading controls: Use established housekeeping proteins (β-actin, GAPDH, tubulin) for normalization, but be aware that their expression may vary across tissue types or experimental conditions. For phospho-CTTN studies, total CTTN protein should be used as the primary normalization control .

• Densitometry approach:

  • Use linear range determination: Create a standard curve with serial dilutions of a positive control sample to ensure quantification occurs within the linear detection range.

  • Apply background subtraction uniformly across all samples.

  • Express data as a ratio of CTTN signal intensity to loading control intensity.

• Technical replicates: Perform minimum triplicate technical and biological replicates to account for technical variability and biological variance.

For Immunofluorescence Quantification:

• Cell-by-cell analysis: Measure fluorescence intensity on a per-cell basis rather than field-average to account for cell heterogeneity.

• Internal reference: Normalize CTTN staining to a cell parameter (cell area, nuclear staining) to account for cell size variations.

• Standardization across experiments: Include a reference sample in each experiment for inter-experimental normalization.

For Immunohistochemistry Analysis:

• Scoring systems: Use standardized scoring systems like H-score (combines intensity and percentage of positive cells) or Allred score.

• Digital pathology: Employ automated image analysis software with consistent thresholding parameters across all samples.

• Pathologist validation: Have quantifications confirmed by multiple independent pathologists to reduce subjective bias.

Statistical Considerations:

• Appropriate statistical tests: Use paired tests for before/after comparisons within the same samples; use unpaired tests for independent sample comparisons.

• Data transformation: Check if data meets the assumptions of parametric tests; if not, consider non-parametric alternatives or appropriate data transformations.

• Multiple comparisons: Apply appropriate corrections (Bonferroni, FDR) when making multiple comparisons to avoid false positives.

When analyzing phosphorylated cortactin, always normalize to total cortactin levels rather than housekeeping proteins to account for variations in total protein expression . Additionally, consider that subcellular localization of cortactin (cytoplasmic vs. membrane-associated) may be functionally significant, so methods that preserve spatial information (like IF) may provide insights beyond total expression levels.

How can I resolve weak or absent signals when using CTTN antibodies?

When confronted with weak or absent signals in CTTN antibody experiments, systematic troubleshooting can help identify and resolve the underlying issues:

For Western Blot Applications:

• Protein degradation: Cortactin (80-85 kDa) is susceptible to proteolytic degradation. Ensure complete protease inhibitor cocktails are added to lysis buffers, and samples are kept cold during preparation .

• Insufficient protein loading: Increase total protein amount (try 50-100 μg per lane) or concentrate samples using TCA precipitation or similar methods.

• Antibody concentration: Adjust primary antibody concentration within the recommended range (1:500-1:2000) . If using a dilution at the higher end, try increasing the concentration.

• Exposure time: For chemiluminescence detection, try longer exposure times or more sensitive substrates (e.g., femto vs. pico sensitivity).

• Transfer efficiency: For large proteins like cortactin, extend transfer time or use specialized transfer methods for high molecular weight proteins.

For Immunostaining Applications:

• Antigen masking: Optimize antigen retrieval methods. If using heat-induced epitope retrieval, test different buffers (citrate pH 6.0 vs. EDTA pH 9.0) and durations.

• Fixation issues: Excessive fixation can mask epitopes. Reduce fixation time or try alternative fixatives (PFA vs. methanol) for immunofluorescence applications.

• Antibody penetration: Increase permeabilization time or concentration (0.1% to 0.3% Triton X-100) to improve antibody access to the antigen.

• Detection sensitivity: Switch to more sensitive detection systems (e.g., tyramide signal amplification or polymer-based detection systems for IHC).

• Incubation conditions: Extend primary antibody incubation time (overnight at 4°C) and ensure adequate washing between steps .

General Considerations:

• Antibody validation: Confirm activity with a positive control sample known to express cortactin (e.g., A431 cells, invasive cancer cell lines).

• Epitope accessibility: If one CTTN antibody fails, try another targeting a different epitope. For example, if the phospho-specific antibody (Y460) yields no signal, test a total cortactin antibody to determine if the protein is present but not phosphorylated .

• Storage conditions: Verify proper antibody storage; degraded antibodies can result in weak signals. Follow manufacturer recommendations for storage at -20°C for long-term and 4°C for short-term use .

• Sample-specific issues: For certain tissues or cell types with low endogenous expression, consider more sensitive detection methods or signal amplification techniques.

By systematically addressing these potential issues, you can significantly improve detection sensitivity while maintaining specificity in your CTTN antibody applications .

What controls should I include to validate specificity in CTTN antibody experiments?

Robust experimental controls are essential for validating CTTN antibody specificity and ensuring reliable research outcomes. Implement the following control strategies:

Essential Positive Controls:

• Known expressors: Include cell lines with documented cortactin expression (e.g., A431 epidermoid carcinoma cells, MDA-MB-231 breast cancer cells) as positive controls for antibody function .

• Recombinant protein: Use purified recombinant cortactin as a positive control in Western blot applications to verify antibody recognition of the target protein.

• Reference tissues: For IHC applications, include tissue sections known to express cortactin (e.g., human breast carcinoma) as described in validation images for commercial antibodies .

Critical Negative Controls:

• Genetic knockdown/knockout: CTTN siRNA/shRNA-treated or CRISPR-Cas9 knockout samples provide the gold standard for antibody specificity validation.

• Blocking peptide: Pre-incubate the antibody with the immunizing peptide (e.g., the sequence corresponding to amino acids 1-200 of human cortactin for CAB15054) . Signal abolishment confirms specificity.

• Secondary-only control: Omit primary antibody but include all other reagents to identify potential non-specific binding of secondary antibodies.

• Isotype control: Use matched isotype IgG (e.g., rabbit IgG for rabbit polyclonal antibodies) at the same concentration as the primary antibody to identify potential non-specific binding .

Phosphorylation-Specific Controls:

• Phosphatase treatment: For phospho-specific antibodies like Anti-Cortactin (Y460), treat a sample with lambda phosphatase to remove phosphorylation and confirm antibody phospho-specificity .

• Stimulation/inhibition pairs: Include samples from cells treated with kinase activators (e.g., EGF, which promotes cortactin phosphorylation) and kinase inhibitors (e.g., Src inhibitors) when using phospho-specific antibodies.

Cross-Reactivity Controls:

• Multiple antibodies: Use different antibodies targeting distinct epitopes of cortactin. Consistent results increase confidence in specificity.

• Species specificity: When working across species, include samples from each species being studied to confirm the antibody's cross-reactivity aligns with manufacturer claims .

Procedural Controls:

• Loading control: Use housekeeping proteins (β-actin, GAPDH) to normalize for loading variations in Western blot applications.

• Reproducibility control: Perform technical replicates to ensure consistent results across multiple experiments.

By implementing these comprehensive controls, researchers can confidently validate antibody specificity, troubleshoot inconsistent results, and produce reliable, reproducible data when working with CTTN antibodies .

How do I interpret discrepancies in CTTN results across different antibodies or techniques?

Discrepancies in CTTN results across different antibodies or techniques are common and require careful investigation to resolve. Here's a systematic approach to interpret and address such inconsistencies:

Understanding the Source of Discrepancies:

• Epitope differences: Different antibodies target distinct regions of the cortactin protein. The H222 antibody and CAB15054 recognize different epitopes, while A01253Y460 specifically detects the phosphorylated Y460 residue . Discrepancies may reflect genuine biological differences in epitope accessibility or post-translational modifications.

• Technical sensitivity variations: Western blotting, immunofluorescence, and IHC have inherently different detection sensitivities. Western blotting can detect smaller changes in expression levels, while IHC provides spatial context but may be less quantitatively precise.

• Sample preparation effects: Different fixation methods can alter epitope availability. Paraformaldehyde fixation may preserve some epitopes while masking others compared to methanol fixation or aldehyde-based fixatives used in FFPE tissues.

Systematic Resolution Approach:

• Validate with orthogonal techniques: If Western blot and IHC results disagree, add a third method such as qRT-PCR to analyze mRNA expression or mass spectrometry for protein identification.

• Antibody validation hierarchy:

  • Genetic approaches: Test antibodies on samples with genetic manipulation of CTTN (knockdown/knockout)

  • Endogenous expression gradient: Compare multiple cell lines with different known expression levels

  • Peptide competition: Confirm specificity through specific blocking with immunizing peptides

• Application-specific optimization:

  • For WB discrepancies: Adjust lysis conditions, as different detergents may extract cortactin with varying efficiencies from different cellular compartments

  • For IF/IHC discrepancies: Systematically compare antigen retrieval methods and detection systems

Interpreting Biologically Relevant Discrepancies:

• Isoform-specific detection: Human cortactin has multiple isoforms resulting from alternative splicing. Antibodies targeting different regions may detect different subsets of isoforms.

• Post-translational modifications: Phosphorylation at Y421, Y466, and Y482 can affect antibody binding . When one antibody shows signal but a phospho-specific antibody doesn't, this likely indicates presence of unphosphorylated protein.

• Subcellular localization differences: Some antibodies may preferentially detect cortactin in specific cellular compartments due to conformational differences or masking by protein-protein interactions.

Documentation and Reporting:

When publishing research with discrepant results:

• Clearly describe all antibodies used (catalog numbers, clonality, epitopes)

• Detail all optimization procedures attempted

• Present results from multiple antibodies or techniques side by side

• Provide biological interpretations for discrepancies rather than dismissing contradictory results

• Include all relevant controls that validate each antibody's specificity

This comprehensive approach transforms discrepancies from experimental problems into potentially valuable insights about cortactin biology, including its regulation, modification state, and compartmentalization within cells.

How can I design experiments to investigate cortactin's role in cancer invasion and metastasis?

Designing experiments to investigate cortactin's role in cancer invasion and metastasis requires multi-faceted approaches that connect molecular mechanisms to cellular phenotypes. Here are methodologically rigorous experimental designs:

1. Expression-Phenotype Correlation Studies:

• Tissue microarray analysis: Analyze cortactin expression in primary tumors versus metastatic lesions using validated antibodies at 1:50-1:100 dilution for IHC-P . Correlate expression with clinical outcomes and invasion depth.

• Patient-derived xenografts (PDX): Establish PDX models from primary and metastatic tumors, then assess cortactin expression and phosphorylation status using both total and phospho-specific antibodies .

• Single-cell analysis: Perform single-cell RNA-seq and protein analysis to identify cortactin-expressing subpopulations within heterogeneous tumors and correlate with invasive phenotypes.

2. Functional Manipulation Studies:

• Genetic modulation systems:

  • CRISPR-Cas9 knockout/knockin: Create complete knockouts or phospho-mutants (Y421F, Y466F, Y482F) to assess the contribution of specific phosphorylation sites to invasion.

  • Inducible expression systems: Use Tet-on/off systems to control cortactin expression timing and observe acute versus chronic effects on cell behavior.

• Domain-specific inhibition: Design experiments using truncated cortactin constructs to identify which domains (SH3, repeat regions) are critical for invasion-related functions.

3. Dynamic Invasion Assays:

• 3D invasion models: Use spheroid invasion assays in collagen/Matrigel matrices, quantifying invasion distance and patterns while simultaneously monitoring cortactin localization via immunofluorescence (1:50-1:200 dilution) .

• Invadopodia assays: Combine gelatin degradation assays with cortactin immunostaining to correlate matrix degradation with cortactin recruitment and phosphorylation.

• Intravital imaging: In animal models expressing fluorescently-tagged cortactin, perform real-time imaging of tumor cell invasion and intravasation in relation to cortactin dynamics.

4. Molecular Interaction Studies:

• Proximity labeling: Use BioID or APEX2 fused to cortactin to identify invasion-specific interaction partners in 2D versus 3D contexts.

• Co-immunoprecipitation: Use antibodies validated for IP (1:50 dilution) to pull down cortactin complexes under different stimulation conditions (EGF, HGF, hypoxia) that promote invasion .

• Phosphoproteomic analysis: Identify kinases responsible for cortactin phosphorylation in invasive contexts and validate using phospho-specific antibodies like Anti-Cortactin (Y460) .

5. Translational Applications:

• Drug screening: Test compounds that disrupt cortactin-dependent invasion, monitoring efficacy via phospho-specific antibodies.

• Biomarker validation: Evaluate whether cortactin phosphorylation status (using phospho-specific antibodies) correlates with treatment response or metastatic potential.

• Patient stratification models: Develop IHC-based scoring systems combining cortactin expression, phosphorylation, and localization to predict invasive potential.

For all these experimental approaches, appropriate controls must be incorporated, including matched primary antibody concentrations for immunological techniques, vehicle controls for drug treatments, and scrambled/non-targeting controls for genetic manipulation studies . This comprehensive experimental strategy will provide mechanistic insights into cortactin's role in cancer progression while generating potential translational applications.

What are the emerging research directions in CTTN antibody applications?

Emerging research directions in CTTN antibody applications are expanding beyond traditional uses, leveraging technological advances and deeper understanding of cortactin biology. These cutting-edge approaches represent the future of cortactin research:

• Multiplexed imaging technologies: Novel applications combine CTTN antibodies with multiplexed immunofluorescence techniques (Imaging Mass Cytometry, CODEX, Cyclic-IF) to simultaneously visualize cortactin alongside dozens of other proteins within the tumor microenvironment. This enables unprecedented spatial analysis of cortactin's interactions with the cytoskeleton, signaling molecules, and immune cells in complex tissues .

• Live-cell phosphorylation dynamics: Emerging techniques pair phospho-specific antibodies like Anti-Cortactin (Y460) with cell-permeable nanobody-based detection systems to monitor real-time phosphorylation changes in living cells, providing insights into the temporal dynamics of cortactin activation during invasion and migration .

• Liquid biopsy applications: Innovative approaches are exploring cortactin detection in circulating tumor cells (CTCs) and extracellular vesicles using highly sensitive immunocapture techniques, potentially establishing cortactin as a minimally-invasive biomarker for metastatic potential.

• Spatial transcriptomic correlation: Advanced methods now combine CTTN immunohistochemistry with spatial transcriptomics to correlate protein expression with local gene expression patterns, revealing potential regulatory mechanisms controlling cortactin expression in different tumor regions.

• Super-resolution imaging applications: Next-generation imaging using STORM, PALM, or STED microscopy with validated CTTN antibodies (1:50-1:200 dilutions) enables visualization of cortactin's nanoscale organization within actin networks and invadopodia, providing unprecedented structural insights .

• Pharmacodynamic biomarker development: CTTN phospho-antibodies are increasingly being utilized as pharmacodynamic biomarkers in clinical trials of kinase inhibitors, particularly those targeting Src family kinases that phosphorylate cortactin .

• Single-cell proteomics integration: Emerging single-cell proteomics approaches incorporate cortactin antibodies to classify tumor cell subpopulations based on cytoskeletal protein expression patterns, potentially identifying invasive or therapy-resistant cellular phenotypes.

• Machine learning image analysis: Computational approaches now apply machine learning algorithms to cortactin immunostaining patterns to identify subtle features associated with disease progression that might be missed by conventional pathological assessment.